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Abstract
Background: To determine association of nine single nucleotide polymorphisms (SNPs) in ADP ribosyltransferase-1
(ADPRT1), aldo-keto reductase family 1 member B1 (AKR1B1), receptor for advanced glycation end-products (RAGE),
glutamine:fructose-6-phosphate amidotransferase-2 (GFPT2), and plasminogen activator inhibitor-1 (PAI-1) genes
with chronic renal insufficiency (CRI) among Asian Indians with type 2 diabetes; and to identify epistatic
interactionss between genes from the present study and those from renin-angiotensin-aldosterone system (RAAS),
and chemokine-cytokine, dopaminergic and oxidative stress pathways (previously investigated using the same
sample set).
Methods: Type 2 diabetes subjects with CRI (serum creatinine ≥3.0 mg/dl) constituted the cases (n = 196), and
ethnicity and age matched individuals with diabetes for a duration of ≥ 10 years, normal renal functions and
normoalbuminuria recruited as controls (n = 225). Allelic and genotypic constitution of 10 polymorphisms (SNPs)
from five genes namely- ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 with diabetic CRI was investigated. The genetic
associations were evaluated by computation of odds ratio and 95% confidence interval. Multiple logistic regression
analysis was carried out to correlate various clinical parameters with genotypes, and to study epistatic interactions
between SNPs in different genes.
Results: Single nucleotide polymorphisms -429 T>C in RAGE and rs7725 C>T SNP in 3’ UTR in GFPT2 gene showed
a trend towards association with diabetic CRI. Investigation using miRBase statistical tool revealed that rs7725 in
GFPT2 was a perfect target for predicted miRNA (hsa miR-378) suggesting the presence of the variant ‘T’ allele may
result in an upregulation of GFPT2 contributing to diabetic renal complication. Epistatic interaction between SNPs
in transforming growth factor TGF-b1 (investigated using the same sample set and reported elsewhere) and GFPT2
genotype was observed.
Conclusions: Association of SNPs in RAGE and GFPT2 suggest that the genes involved in modulation of oxidative
pathway could be major contributor to diabetic chronic renal insufficiency. In addition, GFPT2 mediated
overproduction of TGF-b1 leading to endothelial expansion and thereby CRI seems likely, suggested by our
observation of a significant interaction between GFPT2 with TGF-b1 genes. Further, identification of predicted
miRNA targets spanning the associated SNP in GFPT2 implicates the rs7725 SNP in transcriptional regulation of the
gene, and suggests GFPT2 could be a relevant target for pharmacological intervention. Larger replication studies
are needed to confirm these observations.
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Diabetic chronic renal insufficiency (CRI) is the leading
cause of death due to end stage renal disease world
over. Glycemic control and blood pressure along with
duration of diabetes are major risk factors for develop-
ment of this micro-vascular complication. Familial clus-
tering and the observation that diabetic nephropathy
afflicts only 20-30% of all diabetic patients, indicate a
genetic component underlying disease development.
Further, prevalence of diabetic CRI is also known to
vary between populations, with non-Caucasian diabetic
patients having higher risk than Caucasians [1]. Poly-
morphisms in genes from several biochemical pathways
such as aldose reductase-polyol, di-acyl glycerol-protein
kinase C, non-enzymatic glycation and glycoxidation,
hexosamine pathway, and renin-angiotensin-aldosterone
system (RAAS) have been implicated in the develop-
ment of diabetic chronic renal insufficiency [2]. Many of
these pathway genes have been previously tested for
association with CRI in the Indian population [3-6]. On
the other hand, in experimental models [7,8] and clinical
trials [9] the inhibitors of these individual pathways
failed to block various downstream events leading to
disease development, suggesting that all these hypergly-
cemia mediated pathways could possibly be linked to a
common upstream event. An increase in oxidative stress
through overproduction of superoxide radical by the
mitochondrial electron transport chain was proposed to
be that common event and the initiating factor in dia-
betic kidney disease [2]. Excess production of superoxide
activates all the above mentioned pathways through
deoxyribonucleic acid (DNA) damage mediated activa-
tion of poly adenosine diphosphate (ADP) ribose poly-
merase (PARP) causing inhibition of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), a key glycolytic
enzyme. It has been proposed that the decreased
GAPDH activity upregulates the polyol pathway,
increases intracellular advanced glycation end-product
(AGE) formation, activates protein kinase C (PKC), and
hexosamine pathway flux. In addition, hexosamine path-
way mediates activation of the plasminogen activator
inhibitor-1 (PAI-1) promoter in vascular smooth muscle
cells which is a major factor causing endothelial dys-
function and initiates diabetes related complications [2].
Variants in ADP-ribosyltransferase-1 (ADPRT1), aldo-
keto reductase family 1 member B1 (AKR1B1), receptor
for advanced glycation end products (RAGE), plasmino-
gen activator inhibitor-1 (PAI- 1) and glutamine:fruc-
tose-6-phosphate amidotransferase 2 (GFPT2) genes
have been investigated for their association with differ-
ent disease conditions. Val762Ala and Phe54Leu of the
ADPRT1 gene encoding PARP have been tested for
association with chronic glomerulonephritis in Russian
patients [10]. AKR1B1 variants have been shown to be
associated with diabetic neuropathy [11,12], nephropathy
[13,14] and retinopathy [1,15]. Polymorphisms in RAGE
gene have been implicated for type-1 diabetes, type-2
diabetes and their complications in Caucasian popula-
tions [16-18]. PAI-1 gene polymorphisms are widely
implicated in development of hypertension and obesity.
However, a few reports also indicate their influence in
development of diabetes and its complications [19-27].
Genetic variants in GFPT2 variants are associated with
type 2 diabetes and diabetic nephropathy [28].
We investigated the association of nine functionally
significant polymorphisms in this set of five oxidation
pathways modulation genes (ADPRT1, AKR1B1, RAGE,
GFPT2 AND PAI-1) with CRI among Asian Indians
with type 2 diabetes. Further, it is well known that a
complex disease is a manifestation of interaction
between candidate genes from different biological path-
ways. Numerous cellular pathways (including hexosa-
mine, cytokine-chemokine, advanced glycation end
product, aldose reductase, polyol, and renin-angiotensin-
aldosterone system) are activated by increased glucose
levels and their interaction with each other is believed
to influence development and progression of diabetic
CRI [2]. Therefore, in the present report, which is the
last of the series from our laboratory, we attempted to
identify putative pathological epistatic interactions
between genes from multiple pathways using a com-
bined data set from this study together with data from
all our previous studies carried out using the same sam-
ple set on RAAS [3], chemokine [4], dopaminergic [5],
and oxidative stress [6] genes.
In addition, based on available biological explanations,
independent assessments for epistatic interactions
between glutamine: fructose-6-phosphate amidotransfer-
ase (GFPT2) and transforming growth factor -b1( TGF-
b1); and angiotensin converting enzyme (ACE) and plas-
minogen activator inhibitor-1 (PAI-1) were also carried
out. Under long standing hyperglycemia, the hexosamine
pathway is induced by shunting of excess intracellular
glucose where Fructose-6 phosphate is metabolized into
N-acetyl-glucosamine and thereafter metabolized to gly-
colipids, proteoglycans and glycoproteins. The rate limit-
ing enzyme in hexosamine biosynthesis is GFPT.
Increased concentration of GFPT in mesangial cells
enhances formation of proteoglycans and glycoproteins
which upregulates transcription of TGF-b1, a known
pro-sclerotic agent, and an important causative factor
for development of diabetic nephropathy [29].
For interaction between SNP pair in ACE and PAI-1
genes, the renin-angiotensin-aldosterone system (RAAS)
is speculated to interact with the plasminogen activator
inhibitor (PAI-1) system for regulation of fibrinolysis
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ing enzyme of the RAAS. A beneficial effect of ACE
inhibitor on diabetic kidney disease has been observed
in clinical trials, which underscores the importance of
ACE in diabetic CRI. The 300 bp insertion/deletion (I/
D) polymorphism in intron 16 of ACE has been widely
implicated in diabetic CRI across several populations.
Further, the ACE DD genotype was found to be asso-
ciated with increased PAI-1 activity [30], and ACE inhi-
bition was found to attenuate the peak circulating level
of PAI-1 [31]. Interaction between ACE with PAI-1
gene polymorphisms was found to decrease PAI-1
mRNA expression in irradiated kidney with a role in
modification of intercellular matrix modeling and renal
damage [32]. With this background, in this study, we
investigated epistatic interactions between TGF-b1p r o -
moter (-800 G>A) SNP and rs7725, C>T in GFPT2; and
ACE I/D polymorphism and homozygous Del (4G/4G)
marker of PAI-1 gene pairs.
Methods
Subjects
Complete clinical and demographic characteristics of
the study population have been reported elsewhere (3,
Table 1). Briefly, in this retrospective case-control
study consecutive consenting subjects suffering from
type-2 diabetes with CRI defined as serum creatinine
≥3 mg/dl (n = 196), and diabetics without any evidence
of diabetic kidney disease (diabetes of more than 10
years, normal renal function, no significant proteinuria;
n = 225) were recruited from the outpatient
departments of the participating medical institutions
situated across India. The study was approved by
respective institutional ethics committee and an
informed consent was obtained from all the partici-
pants. 10 ml venous blood was collected from each
individual included in the study for biochemical and
genetic analysis. Biochemical analyses to determine
fasting glucose, glycated hemoglobin, serum creatinine,
triglycerides, total cholesterol, and albumin were car-
ried out at the respective centres using automated ana-
lyzers. Using serum creatinine as a surrogate marker
we calculated glomerular filtration rate (GFR) by using
the online modified diet in renal disease (MDRD) cal-
culator http://www.nephron.com/cgi-bin/MDRD_GFR.
cgi[33]. For CRI, the inclusion criteria were subjects
with type 2 diabetes for ≥ 2 years, plus two or more of
the following: serum creatinine ≥ 150 umol/l, urinary
albumin excretion rate (AER) > 200 mg/l, and presence
of retinopathy. Normoalbuminuric (AER<20 mg/l)
type-2 diabetes subjects of ≥ 10 years duration of dia-
betes (mean duration 17.07 ± 6.69 years) were
recruited as control diabetes subjects. An aliquot of
blood from the four centers was transported to the
genetics laboratory for DNA isolation and
amplification.
Genetic analysis
A total of 10 polymorphisms from five candidate genes
namely- ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1
were genotyped in DM (controls) and CRI (cases) sub-
jects (Table 2). SNPs were selected based on their minor
allele frequency and functional relevance: SNPs leading
to missense mutations, promoter polymorphisms, and
those present in the regulatory regions (5’ UTR and 3’
UTR) were chosen in the same order of priority. Geno-
typing was done using either polymerase chain reaction
(PCR) restriction fragment length polymorphisms
(RFLP) or PCR-length polymorphism (LP) approach.
Digested PCR products werer e s o l v e do n2 - 3 %a g a r o s e
gel stained with ethidium bromide. The PCR primers,
PCR and RFLP conditions and genotypic profiles
obtained for each of the polymorphisms are presented
in Table 2.
Statistical Analysis
Comparison of all clinical variables between DM and
CRI subjects were carried out by c
2 test for nominal
variables or t-test for continuous variables. Hardy-
Weinberg equilibrium was tested for each of the SNPs
based on the genotyping of 220 normal healthy indivi-
duals (average age 35.11 ± 8.98 years). These were
recruited on a random basis from different locations
including public meeting places, offices, colleges, mar-
kets and hospitals and represent population based
Table 1 Clinical characteristics of the study population
Characteristics DM
a
(N = 225)
CRI
b
(N = 196)
P
Gender (M/F) 76/149 65/131 0.89
d
Age (years) 60.6 ± 11.5 57 ± 12.8 0.10
c
Duration of Diabetes (years) 17.07 ± 6.69 10.4 ± 7.7 <0.05
c
Hb A1c (%) 7.3 ± 1.0 7.5 ± 1.1 0.949
c
Systolic pressure (mm Hg) * 140 (106-190) 150 (110-210) 0.002
e
Diastolic pressure (mm Hg) * 84 (80-104) 90 (70-110) 0.025
e
Serum creatinine (μmol/l) * 84 (35-108) 177 (124-1112) <<0.05
e
fUAER (mg/l) * 10 (1-16) 864 (320-1584) <<0.05
e
gGFR (mls/min/1.73 m
2) 81.44 ± 21.85 27.83 ± 24 <<0.05
c
Serum triglyceride (mmol/l) 1.7 ± 0.67 1.8 ± 1.4 0.307
c
Serum cholesterol (mmol/l) 4.8 ± 0.97 4.9 ± 0.92 0.852
c
Retinopathy (%) 24 88
Non proliferative (%) 15 35
Proliferative (%) 8.6 53 <<0.05
d
Cardiovascular events (%) 3 8.3
Data presented as mean ± SD (* median and range).
atype 2 diabetes subjects
without nephropathy (DM);
bwith diabetic renal insufficiency (CRI);
cStudent’st
test;
dPearson’s c
2 test;
eMann-Whitney U test,
fUrinary albumin excretion rate,
gGlomerular filtration rate.
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morphisms were evaluated by Pearson’s c
2 test/Fisher’s
exact test followed by odds ratio (OR) and 95% confi-
dence intervals (CI) computation. P values < 0.05 were
considered significant. Power of the sample size for
each of the SNPs at 5% significance level was calcu-
lated using PAWE software version 1.2 [34,35]. Linear
and multiple logistic regression (Backward) analyses
were carried out to correlate various clinical para-
meters with genotypes, and gene-gene interactions
between SNPs of different pathways. Additive inheri-
tance model in multiple regression analysis was
employed to test interaction between SNP pairs from
different pathways.
The miRBase::Sequence tool was used to identify
miRNA Target in 3’UTR of gene. The .miRBase::
Sequence Database is a searchable database of pub-
lished miRNA sequences and annotation [miRBase::
Sequences http://microrna.sanger.ac.uk/sequences].
Each entry in the miRBase Sequence database
represents a predicted hairpin portion of a miRNA
transcript (termed mir in the database), with informa-
tion on the location and sequence of the mature
miRNA sequence (termed miR).
Results
All the investigations in this study were carried out on
the single sample set (cases 196, controls 225) reported
earlier [3]. Clinical characteristics of the two groups are
shown in Table 1.
Genetic analyses
Polymorphism C>G (rs3738708) in ADPRT1,G > C
(rs5053) in AKR1B1 and -374T>A in RAGE were found
to be monomorphic in this population and not analyzed
further. Remaining seven markers were in Hardy Wein-
berg Equilibrium in the study population. Results of
allelic and genotypic association are presented in Table
3. Bonferroni correction value for the univariate associa-
tion analysis in this study was (b) = 0.05/7 = 0.007.
None of the association observed in the study withstood
the Bonferroni correction.
Table 2 Polymorphisms in ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 genes, their location, primer sequences, PCR
conditions and restriction enzyme with product sizes.
Gene, OMIM No., nucleotide change,
position and rs ID of the polymorphism
Primer sequence Product size (bp) Annealing temp./Restriction
enzyme/allele sizes
ADPRT1 (*173870; 1q42.12)
C>G (Phe54Leu; rs3738708)
F: 5’- TCGAGGTCAAGGTCAAGGTC -3’
R: 5’- CTGTCACTCCTCCAGCTTCC -3’
249 60°C/BsaX I/
C = 106,143 bp
G = 249
ADPRT1 (*173870; 1q42.12)
T>C (Val762Ala; rs1136410)
F: 5’- CCC AAA TGT CAG CAT GTA CG -3’
R: 5’- AGG CCT GAC CCT GTT ACC TT -3’
406 57°C/Ssi I/
T = 406 bp
C = 268 bp, 138 bp
ADPRT1 (*173870; 1q42.12)
A>G (Arg940Lys; rs3219145)
F: 5’- AGA TGG TCT GGG TTT TGT GG-3’
R: 5’- TGA ACC TCC AAT CAT GGT CA -3’
399 57°C/Eco9I1/
A = 399 bp
G = 243 bp,156 bp
AKR1B1 (*103880; 7q35)
5’ UTR G>C (rs5053)
F: 5’-ACT AGG ACC AGG CGG AAG AA -3’
R: 5’- CCG TTG TTG AGC AGG AGA C-3’
234 58°C/Msp I/
G = 154 bp, 80 bp
C = 234 bp
AKR1B1 (*103880; 7q35)
5’ UTR, G>A (rs759853)
F: 5’-ACT AGG ACC AGG CGG AAG AA -3’
R: 5’- CCG TTG TTG AGC AGG AGA C-3’
234 58°C/BfaI/
G = 234 bp
A = 204 bp, 20 bp
RAGE (*600214; 6p21.3)
-374T>A (rs1800624)
F: 5’- AAA ACA TGA GAA ACC CCA GA-3’
R: 5’-CCC CGA TCC TAT TTA TTC CA -3’
222 57°C/Alu I/
T = 222 bp
A = 176 bp, 46 bp
RAGE (*600214; 6p21.3)
-429T>C (rs1800625)
F: 5’- AAA ACA TGA GAA ACC CCA GA-3’
R: 5’-CCC CGA TCC TAT TTA TTC CA -3’
222 57°C/Tas I/
T = 121 bp, 101 bp
A = 222 bp
RAGE (*600214; 6p21.3)
Promoter, 63 bp Ins/Del polymorphism
F: 5’- AAA ACA TGA GAA ACC CCA GA-3’
R: 5’-CCC CGA TCC TAT TTA TTC CA -3’
222 57°C/
Ins = 222 bp
Del = 159 bp
GFPT2 (*603865; 5q34-q35
3’UTR, C>T (rs7725)
F5’-GGCTTTCTGTAGCCGTGGT-3’
R5’-TACTATGGGCAAGGAGCAG-3’
361 bp 58°C/Tsp509I/
C = 361 bp
T = 218,143 bp
PAI-1 (*173360; 7q21.3)
Promoter, PAI-1 4G/5G
F5’-CACAGAGAGAGTCTGGACACGT-3’
R5’- CCCAACAGAGGACTCTTGGTC-3’
101 bp 62°C/Bsl I
4G = 97 bp, 4 bp
5G = 74 bp, 23 bp, 4 bp
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No allelic or genotypic association of T>C (Val>Ala;
rs1136410) and A>G (Arg>Lys, rs3214915) SNPs with
diabetic CRI was observed (Table 3).
AKR1B1
No allelic or genotypic association of the G>A
(rs759853) polymorphism with CRI in our sample set
was seen (Table 3).
RAGE
No allelic association of the -429T>C, 63 bp Ins/Del
polymorphisms with diabetic CRI was observed (Table
3). However, genotype CC of -429T>C SNP exhibited
statistical association on odds ratio calculation (OR:
9.03, 95%CI: 1.09-74.26).
GFPT2
A marginal allelic association of 3’ UTR polymorphism
(rs7725, C>T) with CRI was observed in this study
(Table 3). Allele T seems to confer susceptibility to CRI
(OR: 1.38, 95%CI: 1.02-1.98, P = 0.047). On further
investigation using the miRBase tool it was observed
that 3’ UTR polymorphism (rs7725) was a perfect target
for predicted miRNA (hsa miR-378).
PAI-1
No allelic or genotypic association of PAI-4G/5G (dele-
tion/insertion polymorphism) with diabetic CRI was
observed (Table 3).
Multivariate logistic regression analysis (backward
method) was carried out using disease status as a depen-
dent variable, and age, gender, BMI, duration of dia-
betes, GFR and genotypes of all seven polymorphisms as
independent variables. 3’ UTR polymorphism (rs7725,
C>T) (OR = 1.44, 95%CI 2.02-1.02, P = 0.036) in
GFPT2 was found to be associated with diabetic CRI.
Assessment of epistatic interaction between candidate
genes from different biological pathways, including
RAAS, chemokine, dopaminergic, and oxidative stress
pathways was performed using backward MLR
(SPSS11.0). A significant interaction between GG geno-
type (of -800 G>A SNP in TGFb1 gene) and CC geno-
type (of rs7725, C>T in GFPT2 gene) was observed in
our sample set. A combination of GG and CC genotype
seems to confer protection (OR = 0.63, 95% CI 0.40-
0.97, P = 0.035) against CRI. Gene-gene interactions
analyzed using complete data set from this study and all
Table 3 Allele and genotype frequencies of SNPs in ADPRT1, AKR1B1, RAGE, GFPT2, PAI and their association status
with diabetic CRI, and the power of sample size to detect association at 5% significance level.
SNPs Allele frequency Genotype frequency Association Power (G %)
DM CRI DM CRI Allele Genotype
(n = 225)
(n = 196)
(n = 225) (n = 196) (df = 1) (df = 2)
ADPRT1
T>C
T = 0.91
C = 0.09
T = 0.925
C = 0.075
TT = 0.87
TC = 0.12
CC = 0.01
TT = 0.83
TC = 0.16
CC = 0.01
c
2 = 0.21;
P = 0.64,
P* = 0.13
c
2 = 1.61;
P = 0.45;
P* = 0.11
12
ADPRT1
A>G
A = 0.91
G = 0.09
A = 0.92
G = 0.08
AA = 0.83
AG = 0.17
GG = 0.00
AA = 0.84
AG = 0.14
GG = 0.02
c
2 = 0.07;
P = 0.79;
P* = 0.13
c
2 = 3.3;
P = 0.19;
P* = 0.14
8
AKR1B1
G>C
G = 0.93
C = 0.07
G = 0.93
C = 0.07
GG = 0.86
GC = 0.14
CC = 0.00
GG = 0.89
GC = 0.11
CC = 0.00
c
2 = 0.88;
P = 0.35;
P* = 0.15
c
2 = 0.94;
P = 0.33
(df = 1);
P* = 0.14
0
RAGE
-429T>C
T = 0.87
C = 0.13
T = 0.88
C = 0.12
TT = 0.77
TC = 0.22
CC = 0.01
TT = 0.81
TC = 0.14
CC = 0.05
c
2 = 0.04;
P = 0.84;
P* = 0.11
c
2 = 8.68;
P = 0.013;
P* = 0.015
OR = 9.03, 95%
CI = (1.09<OR<74.26)
7
RAGE
63 bp ins/del
Ins = 0.96
Del = 0.04
Ins = 0.97
Del = 0.03
Ins/Ins = 0.95
Ins/Del = 0.05
Del/Del = 0.00
Ins/Ins = 0.91
Ins/Del = 0.09
Del/Del = 0.00
c
2 = 0.26;
P = 0.60;
P* = 0.15
P* = 0.06 12
GFPT2
C>T
C = 0.78
T = 0.22
C = 0.72
T = 0.28
CC = 0.50
CT = 0.45
TT = 0.05
CC = 0.60
CT = 0.37
TT = 0.03
c
2 = 3.92;
P = 0.047;
P* = 0.03
OR = 1.38, 95%
CI = (1.02<OR<1.98)
c
2 = 4.5;
P = 0.11;
P* = 0.04
51
PAI-1 4G/5G (del/ins) 4G = 0.52
5G = 0.48
4G = 0.49
5G = 0.51
4G4G = 0.23
4G5G = 0.52
5G5G = 0.25
4G4G = 0.29
4G5G = 0.46
5G5G = 0.25
c
2 = 0.84;
P = 0.36;
P* = 0.06
c
2 = 2.5;
P* = 0.29
14
P:P value for Pearson’s chi-square test
P*: Fisher’s exact P value.
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action between TGF b1 and GFPT2 genes.
GFR (glomerular filtration rate) is a linearly distribu-
ted clinical parameter crucial in determining the extent
of kidney damage, and therefore may act as a shadow
marker for kidney disease. Therefore, a linear regression
analysis was carried out using GFR values as a depen-
dent variable and various genetic markers and clinical
parameters (age, gender, BMI, duration of diabetes) as
independent variables. We did not observe association
of any of the independent variables with GFR.
Discussion
Association studies using polymorphisms in genes from
classical pathways such as aldose reductase-polyol, di-
acyl glycerol-protein kinase C, non-enzymatic glycation/
glycoxidation, hexosamine pathway and renin-angioten-
sin-aldosterone system (RAAS) have identified certain
major and minor susceptibility modifiers which contri-
bute to development of diabetic chronic renal insuffi-
ciency [36-38]. Contemporarily it is believed that an
upstream oxidative stress event may be the master
switch regulating all the above mentioned hyperglycemia
mediated pathways and thus mediate development and
progression of diabetic kidney disease [2]. However, like
in all other complex traits, the results have been incon-
sistent across studies. Therefore, considering the impor-
tance of ADPRT1 as marker of PARP, AKR1B1, RAGE,
GFPT2 and PAI-1 genes in regulation of superoxide
production, association analysis of functionally signifi-
cant variants in these genes becomes imperative. Present
analysis indicates that SNPs -429 T>C in RAGE and
rs7725 C>T in 3’ UTR in GFPT2 gene (Table 3) could
be probable genetic contributor to CRI.
Micro- and macrovascular diabetic complications are
influenced by formation of advanced glycation end pro-
ducts (AGEs) [39], which occur at an accelerated rate
under long standing hyperglycemia. AGEs alter vascular
functions by their formation on the extracellular matrix
altering vascular structure and trapping circulatory pro-
teins, leading to a narrowing of the lumen [39,40]. In
addition, formation of AGEs on intracellular proteins
and DNA leads to cellular changes. The principle means
of derangement of AGEs is by specific AGE-binding
receptors, which include the AGE-receptor complex, the
macrophage scavenger receptors, and the receptor for
AGE (RAGE). Latter is a member of immunoglobulin
super-family located at chromosome 6p21.3 in the MHC
locus [41] and is the most widely implicated by linkage/
association studies. Major up-regulation of RAGE in
vasculature has been observed in diabetic individuals
and animal models in the presence of vascular disease.
Animal models engineered to over-express RAGE
develop diabetic nephropathy more rapidly than their
normal counterparts [42].
The two functional promoter polymorphisms (-374
T>A and -429 T>C) in RAGE are known to alter tran-
scription levels. -374T allele has been seen to confer
protection against chronic heart disease, ischemic heart
disease and atherosclerosis in diabetic patients [43]. This
marker notably is monomorphic in our population. 10%
of the samples were re-genotyped to rule out genotyping
error. On the other hand CC genotype of -429 T>C
SNP is predisposing (OR: 9.03, 95% CI: 1.09 - 74.26) to
diabetic CRI. This observation derives support from an
earlier report of an increased expression of RAGE gene
in the presence of -429C, -374A and 63 bp D alleles
[44]. A heterozygote excess of this marker in our control
(DM) group may be masking the allelic association of
this variant. Further, the very low frequency (0.01) of
CC homozygotes in the control group may be suggestive
of its potential nature to confer major susceptibility to
severe kidney impairments. However, the power to
detect association of this SNP is very low (G = 7%) and
therefore should not be over-interpreted. To overcome
the limitation posed by small sample size and to repli-
cate our result we are currently genotyping all the SNPs
analysed in the study on a larger sample set.
Increased flux of glucose through the hexosamine bio-
synthetic pathway has been implicated in diabetes and
diabetic nephropathy. The rate-limiting enzyme is gluta-
mine: fructose-6-phosphate amidotransferase (GFPT 2),
which catalyzes the formation of glucosamine-6-phos-
phate from glucosamine and fructose-6-phosphate. Up-
regulation of hexosamine pathway has been seen to
influence TGF b1 production in the mesangial cells of
rat kidney [45,46], which is a key molecule in the patho-
genesis of diabetic nephropathy. A study involving Afri-
can-American subjects reported a significant association
of ‘T’ allele of the 3’ UTR SNP with diabetic nephropa-
thy [28]. With this knowledge, the trend of association
of ‘T’ allele of rs7725 in 3’ UTR in GFPT2 that we
observed is exciting and warrants further investigation.
‘T’ allele of rs7725, C>T in GFPT2 has been shown to
be approximately 2-fold over-expressed resulting in
increased mRNA levels with resultant increased hexosa-
mine flux [28]; which in turn has been speculated to
increase extra-cellular matrix (ECM) synthesis and accu-
mulation finally leading to loss of kidney function [47].
Such a transcriptional control exerted by this 3’UTR
SNP may now be convincingly explained by the recent
knowledge that the wild type allele of this SNP is a per-
fect target site for predicted miRNA (hsa miR - 378)
using miRBase::Sequences tool http://microrna.sanger.ac.
uk/sequences. The presence of the variant ‘T’ allele may
result in up-regulation of GFPT2.
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viously reported a significant association of a compound
group of genotypes ‘GA and AA’ of SNP G>A -800 in
TGF b1 gene which was found to be predisposing (P =
0.035; OR: 3.028; CI: 1.079-8.50) and GG was found to
be protective against CRI in a subset of the patients
with proliferative retinopathy [4]. TGF b1 has been
known to influence almost every pathway implicated in
development of diabetic CRI [4]. Considering the above
discussed role of both GFPT 2 and TGF-b1i np a t h o -
genesis of diabetic nephropathy, our findings of gene-
gene interactions of TGF-b1 and GFPT2 genotypes may
suggest that these two genes are major determinants of
CRI in our population (Please see result section). Not-
withstanding these interesting findings in this study
which fulfils most of the criteria of a good genetic asso-
ciation analysis [3], the moderate sample size and
absence of replication in an independent cohort may
pose as study limitations.
Conclusions
This study indicates a trend towards association of -429
T>C polymorphism in RAGE and rs7725 in the 3’ UTR
in GFPT2 genes with diabetic renal disease in Indian
subjects. The study also shows a significant gene-gene
interaction between GFPT 2 and TGF-b1.T h e s eo b s e r -
vations are patho-physiologically important and warrant
replication in a larger sample set.
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